ProCE Banner Activity

Experts Discuss Key Questions in Targeted Therapy for Advanced Biliary Tract Cancer

Clinical Thought

In this focused commentary, 3 experts answer questions posed at an ASCO 2024 symposium regarding the use of immunotherapy and targeted therapy in treating advanced BTC. 

Released: July 23, 2024

Expiration: July 22, 2025

Share

Faculty

Mitesh J. Borad

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

James J. Harding

James J. Harding, MD

Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Disclosure

Primary Author

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Mitesh J. Borad, MD: consultant/advisor/speaker: Merck, Servier; researcher: Relay.

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Lipika Goyal, MD, MPhil: researcher: Alyssum Therapeutics, Boehringer Ingelheim, Genentech; consultant: AbbVie, Agenus, Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Relay Therapeutics, Servier, Surface Oncology, Taiho, TransThera Biosciences, Tyra Biosciences; data and safety monitoring board: AstraZeneca.

James J. Harding, MD

Gastrointestinal Oncology Service
Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

James J. Harding, MD: researcher: AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate Biopharma, Loxo@Lilly, Novartis, Polaris, Pfizer, Tvardi, Zymeworks, Yiviva; consultant: Adaptimmune, AstraZeneca, Bristol Myers Squibb, Eisai, Elevar, Exelixis, Hepion, Imvax, Merck (DSMB), Medivir, QED, RayzeBio, Servier, Tempus, Tyra.